EFFORTS — PO Box 20241
Kansas City, MO 64195–0241

Phone: (877) 2–ENDCOPD
The information on (or referenced by) the EFFORTS’ website and discussion lists is not intended or implied to be a substitute for the professional medical advice of your own healthcare providers.

When you shop at Amazon.com, please use this link to help support EFFORTS.

AmazonSmile

Amazon sends collected donations to charities quarterly. Thanks for your participation.

As a patient advocacy group, we rely on your contributions/donations to maintain the mail list group, this website, and help board members attend conferences and to increase our participation in research.


COPD Studies, Support, Contacts & Education


🗣💨 • November is COPD Awareness Month • O2

November is National COPD Awareness Month in 2022 - NIH: Learn More Breathe Better® program

November is Alpha-1 Awareness Month in 2022 - Alpha-1 Foundation: “Let’s Cure It”



New Meds, Trials, and Studies

MAC Lung Infection

Have you been recently/newly diagnosed with a MAC lung infection? MAC is the most common form of nontuberculous mycobacteria (NTM). NTM are bacteria commonly found in the environment. MAC can get inside your lungs when you breathe them in and can affect certain people more than others. Most people who come in contact with MAC do not develop an infection. However, some individuals are at a greater risk of developing an infection called MAC lung disease. MAC lung disease is a serious condition. If untreated, it can cause damage to the lungs.

A new study is looking for individuals with newly diagnosed MAC lung disease who may be interested in participating in a clinical study that is evaluating a drug for potential treatment of MAC lung infections and for the potential to improve symptoms of MAC lung infection including decreased respiratory discomfort and decreased fatigue.

Your participation in the study could potentially contribute to advancements in MAC lung disease research.

You can visit https://www.patientwing.com/ntmstudy-arise-encore-COPD for more information and to see if you may qualify. If you qualify to enroll, and decide to participate, you will be assigned to one of two studies investigating MAC lung disease. Study open as of November 26, 2022

Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (AERIFY-2) dated Mar 23, 2022, sponsored by Sanofi Study open as of November 26, 2022

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation (NOTUS) dated Feb 10, 2022, sponsored by Sanofi Study open as of November 26, 2022

💠 COmmunity Patients at Risk of Viral Infections Including SARS-CoV-2 (CORVIS)See Article: UK Trial Recruiting Patients to Test At-home Nitric Oxide Nebulizer dated April 26, 2021, sponsored by Thirty Respiratory Limited Study open as of November 26, 2022

🅰 Evaluation of the Safety and Efficacy of TLD in Patients With COPD (AIRFLOW–3) Nuvaira Lung Denervation System (Nuvaira System), Nuvaira’s Targeted Lung Denervation Therapy Shown to Lower Hospitalization Risk and see News “Nuvaira Hopes” dated September 11, 2019, sponsored by Nuvaira, Inc. Study open as of November 26, 2022

RejuvenAir® System Trial for COPD With Chronic Bronchitis (SPRAY–CB) sponsored by CSA Medical, see also RejuvenAir® Study open as of November 26, 2022

LEEP Losartan Effects on Emphysema Progression LEEP is a randomized clinical trial evaluating the effect of Losartan in helping people with Chronic Obstructive Pulmonary Disease (COPD) with emphysema – a disease of the lungs. We are looking for adults 40 years of age or older, current or former smokers, with COPD to join our study. The study is conducted in different states across the country. Study open as of November 26, 2022

🚬 Insight COPD Intervention Study In Overweight Patients with COPD We are trying to find out if a program proven to help people lose a modest amount of weight and increase their physical activity will improve COPD symptoms for those with a high BMI. To be in the study, you will need to have COPD, high BMI, history of smoking, shortness of breath, and be 40 years or older. Study open as of November 26, 2022

🚬 RETHINC REdefining Therapy IN early COPD The purpose of the RETHINC study is to determine whether symptomatic current and former smokers with normal lung function will benefit from the use of bronchodilator therapy currently used to treat patients who have Chronic Obstructive Pulmonary Disease (COPD). Study open as of November 26, 2022


🧪 Chronic Obstructive Pulmonary Disease Clinical Trials at UCSF 🧪 Trial list upated at least twice a week 🧪 Study open as of November 26, 2022

Emphysema/COPD Research Registry [PA only] Have COPD, 40 and up, 10 year smoking history Study open as of November 26, 2022

Pulmonary Fibrosis Click the link to find many clinical trials avilable offered for Idiopathic Pulmonary Fibrosis, Cystic Fibrosis, Pulmonary Fibrosis by Clinicaltrials.gov Current as of November 26, 2022

COPD Foundation Research Click Research on the main menu

📋 Find a Clinical Trial 📋 American Lung Association 📋

Clinical Trials GPS Find Trials by the US State

Center Watch List Find Trials across the World

ClinicalConnection Find US and International Trials

US NIH ClinicalTrials.gov Searched for trials for COPD, Chronic Obstructive Pulmonary Disease, Lung Disease, Lungs and more


Everyday Support & Explanations

COPD Pocket Consultant Guide App iOS and Android, Support the treatment and management of COPD, therapy chart with the latest medications, inhaler instruction videos, depression and anxiety screeners, a new pulmonary referral checklist and much more

Educational Videos and Pocasts Learn about COPD and healthier living New Videos added October 2022

Glossary of COPD Words and Terms

DailyMed Official provider of FDA label information

Haven’t Seen a Doctor and Not Sure if You Have COPD? Take the Canadian Lung Health Test

Causes, Symptoms, & Overviews
- Breathing Techniques
- Coping with Everyday Tasks
- Diagnosis & Testing
- Doctor Visits
- Exacerbations & Panic Attacks
- Exercise, Rehabilitation
- Medicines & Devices
- Nutrition
- Oxygen, Oxygen Equipment & Oximeters
- Personal Accounts of Lung Transplant Approvals
- Sleep Disorders, Apnea
- Stem Cell Article from Jim Nelson
- Surgery (Transplant, LVRS, BVR, Stents)
- Travel (including O2 on airlines)

⭐ COPD Exacerbations: A Patient and Physician’s Perspective John Linnell, John R Hurst November 8, 2019

Suggested Inhaler Sequence — Previous
Suggested Inhaler Sequence — Current


Oxygen Manifesto, Oxygen Manifesto, Part 1: Advice from 3 Respiratory Specialists Noah Greenspan, Mark W Mangus Sr, RRT, RPFT, FAARC, & Oxygen Expert Ryan Diesem Published March 27, 2019

Oxygen Manifesto, Oxygen Manifesto, Part 2: the Devices (Advice from 3 Respiratory Specialists) Noah Greenspan, Mark W Mangus Sr, RRT, RPFT, FAARC, & Oxygen Expert Ryan Diesem Published June 19, 2019

Oxygen Manifesto, Oxygen Manifesto, Part 3: Tips and Tricks from 3 Respiratory Specialists) Noah Greenspan, Mark W Mangus Sr, RRT, RPFT, FAARC, & Oxygen Expert Ryan Diesem Published August 5, 2019

COPD Foundation: Oxygen Therapy



      




Finding Insurance, Reinbursement and other Financial Assistance

Medicare, Medicaid and Social Security

Medicare.gov: Find and Compare Information about Hospitals

Getting Assistance: From the Government, Social Services and other Misc Places


Must Read Publications

COPD Foundation’s Slim Skinny Reference Guide®

Adventures of an Oxyphile 2 Free Audiobook download of the second edition

PulmCCM Free weekly email with latest in pulmonary and critical care

The Pulmonary Paper This is a paid subscription


         Click here for more books



_